Chris Arendt und Takeda - Info zur Person

(1 - 19 von 59

)

Crescendo Biologics' Second Oncology-targeted Humabody Licensed by...

www.finanznachrichten.de

Chris Arendt, Head, Oncology Drug Discovery Unit Immunology Unit, Takeda, commented: "We are pleased that our partnership with Crescendo has continued to be fruitful in leading to another ...

Börse Express - News

www.boerse-express.com

"Wir freuen uns auf die Zusammenarbeit mit Curadev, um die Entwicklung dieses innovativen STING-Agonisten fortsetzen zu können", so Chris Arendt, Leiter der Abteilung für onkologische Arzneimittelforschung von Takeda. "Dieses Projekt stellt Takedas Engagement in Bezug auf die Zusammenarbeit mit Weltklasse-Partnern wie Curadev unter Beweis.

Curadev Announces Licensing Agreement With Takeda for Novel STING...

pipelinereview.com

Curadev Announces Licensing Agreement With Takeda for Novel STING Agonist

Curadev Announces Licensing Agreement With Takeda for Novel STING...

www.prnewswire.com

... to collaborating with Curadev to further develop this novel STING agonist," said Chris Arendt, Head Oncology Drug Discovery Unit, Takeda.

Crescendo Biologics’ Second Oncology-targeted Humabody® Licensed by...

www.businesswire.com

Chris Arendt, Head, Oncology Drug Discovery Unit & Immunology Unit, Takeda, commented: “We are pleased that our partnership with ...

Takeda Announces 12 New Molecular Entities with the Potential for

www.businesswire.com

... Andy Plump, President, R&D. Oncology and Cell Therapies with Spotlight on CAR-NK, Chris Arendt, Head, Oncology Drug Discovery Unit.

▷ Curadev meldet Lizenzvereinbarung mit Takeda für ...www.presseportal.de › ...

www.presseportal.de

... dieses innovativen STING-Agonisten fortsetzen zu können", so Chris Arendt, Leiter der Abteilung für onkologische Arzneimittelforschung von ...

Takeda eröffnet neue Produktionsstätte zur …

de.finance.yahoo.com

· „Wir arbeiten mit einigen der besten Wissenschaftler und Innovatoren der Welt zusammen, um eine hoch differenzierte immunonkologische Pipeline aufzubauen, die in neue Modalitäten und Mechanismen mit heilendem Potenzial vorstoßen kann", so Dr. Chris Arendt, Leiter der Onkologie-Therapieeinheit von Takeda.

ImaginAb signs multi-party collaboration agreement with three global...

www.trivano.com

Chris Arendt, Head of the Oncology Drug Discovery Unit at Takeda, said: "We are excited to participate in this pre-competitive alliance, which brings together a rich network of expertise and resources to develop and evaluate an imaging tracer for CD8+ T cells.

Takeda Oncology übernimmt führende Rolle bei ...de.style.yahoo.com › takeda-oncology-übernimmt-führen...

de.style.yahoo.com

... die auf die akuten Bedürfnisse von Patienten mit Blutkrebs wie Leukämien, Lymphomen und Myelomen eingehen", so Chris Arendt, Head, ...

Crescendo Biologics announces early licensing by Takeda of first...

www.biospace.com

Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody® - read this article along with other careers information, tips and...

Crescendo Biologics’ Second Oncology-targeted Humabody® Licensed by...

www.biospace.com

Crescendo Biologics’ Second Oncology-targeted Humabody® Licensed by Takeda - read this article along with other careers information, tips and advice on BioSpace

Takeda earns win for its TKI inhibitor in tiny lung cancer groupendpts.com › takeda-earns-win-for-its-tki-inhibitor-i...

endpts.com

According to Chris Arendt, Takeda's head of oncology, the pooled results show promise for exon 20-positive patients, who make up about 10% of the total EGFR ...

Guest Post: Takeda seeks ‘new normal’ for cancer research during the...

catalyst.phrma.org

“The new normal” has been used to describe the challenging and dynamic cir…tances we find ourselves navigating during the COVID-19 pandemic. But the...

Takeda Jumps Into the Land of CAR-T R&D With New Tie-Up | BioSpace

www.biospace.com

Takeda Jumps Into the Land of CAR-T R&D With New Tie-Up - read this article along with other careers information, tips and advice on BioSpace

Takeda Strikes Potential $1 Billion Oncology Deal with Turnstone |...

www.biospace.com

The two companies will pair up to advance Turnstone’s lead program, RIVAL-01, in multiple cancer studies and will also work together to identify additional...